BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
Reputational Risks
Retatrutide's Illicit Market: What the Surge in Unlicensed "Research Peptide" Sales Means for UK Labs
An investigative report from CBS News published on 8 June 2026, combined with MHRA enforcement raids in the UK and a 265% rise in US poison centre exposures, has brought renewed scrutiny to the grey and black markets for retatrutide. For legitimate research procurement teams, the episode illustrates exactly why the "research-use only" label is under intensifying regulatory pressure on both sides of the Atlantic.
04 Jul 2026
Reputational Risks
MHRA Turns Its Attention to UK Peptide Clinics: What the April 2026 Investigation Means for Legitimate Research Labs
The MHRA has opened investigations into UK clinics making therapeutic claims about unregulated peptide products, following a Guardian exposé and an earlier Criminal Enforcement Unit raid in Lincolnshire. For research-procurement professionals, the enforcement shift clarifies where regulatory tolerance ends — and why robust research-use-only labelling and sourcing discipline matter more than ever.
02 Jun 2026
Reputational Risks
GLP-1 Popularity Is Fuelling Unverified Peptide Promotion Online — and Raising Purity Concerns for Research Procurement
The clinical success of injectable GLP-1 drugs has triggered a surge of social media promotion for a much broader range of unverified peptides, with physicians warning that many products contain minimal active ingredient or outright contaminants. For research-procurement professionals, the same market dynamics create real supply-chain risks that standard vendor screening must address.
19 May 2026